5-Amino-1MQ belongs in a small-molecule research category, despite appearing in many peptide catalogs. Interest centers on inhibiting nicotinamide N-methyltransferase, or NNMT. The selected evidence supports studying that target in metabolism and muscle repair; it does not establish a consumer weight-loss or anti-aging treatment.
Amyloid-beta, often abbreviated Aβ, is a family of protein fragments studied in Alzheimer disease biology. It can be a measured biomarker, an experimental reagent or a treatment target. Those roles do not make amyloid-beta itself a memory supplement or an established therapy.
Adiponectin is a protein hormone associated with fat tissue and metabolic signaling. Many papers measure its concentration while testing another intervention. That makes adiponectin an outcome or biomarker in those studies, not the treatment being given.
Argireline is a synthetic hexapeptide studied in topical wrinkle formulations. The selected human studies give mixed results: one reported improved peri-orbital wrinkle measures, while a later small split-face study found no significant benefit from adding Argireline to the tested serum.
B7-33 is a synthetic peptide modeled on part of relaxin-2 and investigated for signaling through relaxin family peptide receptor 1. Selected animal and cell experiments report vascular and cardiac effects. They are a basis for further research, not proof of a human cardiovascular or antifibrotic treatment.
Cardiogen is a named synthetic tetrapeptide studied in organotypic rat-heart cultures. These experiments examine tissue growth and molecular markers outside a living patient. They do not demonstrate treatment of heart failure, arrhythmia or a heart attack in people.
Cartalax is indexed by the US National Library of Medicine under alanyl–glutamyl–aspartic acid, also called AED or T-31. The directly identifiable primary studies reviewed here concern kidney cultures and rat kidney injury. They do not substantiate a claim that Cartalax rebuilds human cartilage.
Decapeptide-12 is investigated as a topical pigmentation ingredient. A small controlled melasma pilot and later studies of multi-product skin-care systems provide preliminary human evidence. Their scale and formulation differences limit broad claims about every product containing the peptide.
Epitalon is a tetrapeptide studied in cell biology and animal aging experiments. Telomere changes and selected mouse outcomes are research findings; they are not proof that Epitalon extends human lifespan or reverses biological aging. The distinction matters because an appealing mechanism can be marketed as a clinical result long before it is tested that way.
FOXO4-DRI is an experimental peptide associated with research on disrupting the FOXO4–p53 interaction in senescent cells. The influential primary study tested cellular mechanisms and mouse outcomes. It provides a research rationale for targeting some senescent cells, not proof that a commercial preparation reverses aging in people.
Growth differentiation factor 11, or GDF-11, is a signaling protein investigated in development, blood biology and aging. Measuring its concentration in people is not the same as administering it. The selected human studies do not establish that raising GDF-11 improves health or reverses aging.
GHK-Cu is a copper complex of the tripeptide glycyl-histidyl-lysine. It is discussed in skin-care and tissue-repair research, but the route and formulation are essential to interpreting a claim. A skin product tested after a procedure is not evidence that injecting GHK-Cu improves skin, hair or whole-body repair.
GLOW is a name used for combinations of peptides rather than one universally defined molecule. This guide concerns blends listing BPC-157, a thymosin-related ingredient and GHK-Cu. A useful assessment starts with the actual ingredient identities and amounts, because the label alone does not define a reproducible intervention.
GLP-1, or glucagon-like peptide-1, is a hormone name. It is also used informally to describe medicines that act at the GLP-1 receptor. Those uses should be separated: evidence for a named medicine and formulation is not evidence for a vial labeled only “GLP-1.”
Glutathione is a tripeptide involved in cellular redox biology. That biological role does not mean every supplement or infusion improves health. The important questions are what preparation was given, whether it changed a meaningful outcome, and whether that outcome was compared with a suitable control.
Human growth hormone is a protein hormone; somatropin is a recombinant medicinal form. Product-specific clinical uses should be distinguished from claims that raising hormone levels rejuvenates otherwise healthy adults. Body-composition changes alone do not establish longer life, greater independence or improved athletic function.
Human relaxin-2 is a hormone studied through recombinant serelaxin preparations in cardiovascular and other disease settings. Early promising signals were not consistently confirmed in larger clinical trials. A balanced account should include that development history rather than present vascular mechanisms as proof of heart protection.
Humanin is a short peptide investigated for cellular protection in models relevant to neurodegeneration and other stresses. The selected original experiments are laboratory studies. They help identify biological questions, but do not establish that a Humanin product improves memory, treats dementia or slows aging in people.
Afamelanotide, also called Melanotan I, is used in an approved implant for adults with erythropoietic protoporphyria. This does not approve online tanning preparations.
MOTS-c is a 16-residue mitochondrial-derived peptide studied in metabolism and exercise biology. Mouse administration and human exercise observations answer different questions.
NAD+ is a metabolic coenzyme. Direct NAD infusion, precursor supplementation and cellular NAD measurements are different interventions and should not share one efficacy claim.
SLU-PP-332 is a synthetic small-molecule agonist of estrogen-related receptors. Mouse studies examine exercise-like metabolic responses; it is not a peptide or a proven exercise replacement.
Elamipretide, also called SS-31, is the ingredient in Forzinity, approved for a defined Barth-syndrome population. That narrow approval does not establish general anti-aging use.
Tesamorelin is a GHRH analogue approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management.
Thymalin is a thymus-derived polypeptide complex studied in immune-related settings. A mixture, its proposed constituent peptides and a clinical treatment protocol are separate evidence questions.